Viking Therapeutics, Inc.
Metabolic-disease biotech developing dual GLP-1/GIP agonist VK2735 in Phase 3 obesity development.
Obesity & metabolic disease · Peptide receptor agonists & small molecules · Phase 3
Metabolic-disease biotech developing dual GLP-1/GIP agonist VK2735 in Phase 3 obesity development.
Obesity & metabolic disease · Peptide receptor agonists & small molecules · Phase 3